Full-Time

Surgery Technician 2

Posted on 5/9/2026

Inotiv

Inotiv

1,001-5,000 employees

Global CRO for life sciences research

No salary listed

Indianapolis, IN, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Desire to work with and care for animals on a daily basis
  • Interest in animal surgery and care
  • Continuous effort toward contributing to a clean and safe working environment
  • Ability and willingness to complete paperwork as needed
  • Must be available to work weekends/ holidays on a rotating basis
  • Willingness to work overtime when needed
  • Minimum, 2 year degree in animal science; pertinent work experience (such as laboratory, veterinary or surgical experience) may be substituted for education
  • Ability to understand the written company standards and verbal instructions in English
  • Basic math skills
  • Respect for animal welfare
  • Ability to work in a team atmosphere
  • Leadership skills
  • Adherence to the company domestic pet policy and biosecurity
  • Lift up to 50lbs on occasion
  • Stand/walk on concrete for at least 2 hours at a time
  • Frequently bend, reach, push, pull, squat and lift
  • Ability to read, write, and speak English
Responsibilities
  • Cares for animals including feeding, cleaning and surgery support responsibilities
  • Follows protocol to ensure the health and welfare of the animals in care
  • Surgery support tasks including preparation of surgical instruments and supplies for surgeons’ use, operate the autoclaves, calibration of animal weight scales, disinfecting surgery equipment, transfer of animals, and weighing animals
  • Successfully performs rodent catheterization and soft tissue removal surgeries
  • Works with managers in the development of new surgical models
  • Works with managers in the implementation of new and better surgical techniques
  • Trains new Support Technicians and Surgeons
  • Suggests improvements to work instructions in accordance with the 3 Rs (Refine, Replace and Reduce)
  • Inventory control of drugs, including checking expirations dates, calculating concentrations of drugs, accurately maintaining and daily review of the inventory of controlled drugs
  • Coordinates order details to include selection, packaging and confirming accuracy
  • Keeps accurate records of feeding, cleaning and care of animals
  • Animal anesthesia, prep, and post-operative care of surgical animals
  • Ensures animal welfare, with IACUC and quality standards is met within area of responsibility, which includes compliance to work procedures
  • All other duties as assigned

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Simplify Jobs

Simplify's Take

What believers are saying

  • Ranked 182nd on 2025 Deloitte Technology Fast 500 with 448% growth.
  • FY2025 revenue reached $513.0M with $138M DSA backlog.
  • Raised $27.6M via equity offerings in December 2024 for expansion.

What critics are saying

  • Qilin ransomware attack in August 2025 disrupts operations and data.
  • $11M Animal Welfare Act fine for beagle mistreatment triggers USDA scrutiny.
  • FDA prioritizes non-animal testing, slashing demand for animal models.

What makes Inotiv unique

  • BASi merged with Seventh Wave in 2018, combining analytical and preclinical expertise.
  • Acquired Envigo in November 2021, expanding research models and services.
  • Partners with VUGENE on December 11, 2025, integrating AI-driven bioinformatics.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Inotiv who can refer or advise you

Benefits

Health Insurance

Pension

Life Insurance

Wellbeing Program

Paid Time Off

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Paid Holidays

Short-term Disability

Long-term Disability

Dental Insurance

Vision Insurance

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Flexible Benefits Scheme

Employee Assistance Program

Private Health Insurance

Health cash plan

Retail discounts

Education allowance

Tuition Reimbursement

Meal Benefits

Adoption Assistance

Company News

Stock Titan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

Stock Titan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...

CSIMarket
Dec 15th, 2024
Inotiv Inc. Raises $3.6M Equity Funding

Inotiv, Inc. raised $3.6 million through an equity offering of 900,000 shares at $4.25 each, following a previous offering that raised $24 million. The total $27.6 million will support its development and expansion efforts. Despite a current share price of $4.22, slightly below the offering price, Inotiv's stock has risen 32.54% over the past year, reflecting investor confidence. The capital injection aims to enhance Inotiv's market position in drug discovery and development services.

GlobeNewswire
Sep 16th, 2024
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity

WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research...